Global and United States Alpha- Antitrypsin Deficiency Treatment Market Report & Forecast 2024-2031

Report ID: 1838833 | Published Date: Oct 2024 | No. of Page: 108 | Base Year: 2023 | Rating: 4.7 | Webstory: Check our Web story
1 Study Coverage
    1.1 Alpha- Antitrypsin Deficiency Treatment Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Alpha- Antitrypsin Deficiency Treatment Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
        1.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size for the Year 2017-2028
    1.3 Alpha- Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Alpha- Antitrypsin Deficiency Treatment in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Alpha- Antitrypsin Deficiency Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Alpha- Antitrypsin Deficiency Treatment Market Dynamics
        1.4.1 Alpha- Antitrypsin Deficiency Treatment Industry Trends
        1.4.2 Alpha- Antitrypsin Deficiency Treatment Market Drivers
        1.4.3 Alpha- Antitrypsin Deficiency Treatment Market Challenges
        1.4.4 Alpha- Antitrypsin Deficiency Treatment Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Alpha- Antitrypsin Deficiency Treatment by Type
    2.1 Alpha- Antitrypsin Deficiency Treatment Market Segment by Type
        2.1.1 CT-2009
        2.1.2 POL-6014
        2.1.3 ARO-AAT
        2.1.4 ALNAAT-02
        2.1.5 Others
    2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017, 2022 & 2028)
    2.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028)
    2.4 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017, 2022 & 2028)
    2.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028)
3 Alpha- Antitrypsin Deficiency Treatment by Application
    3.1 Alpha- Antitrypsin Deficiency Treatment Market Segment by Application
        3.1.1 Clinic
        3.1.2 Hospital
        3.1.3 Others
    3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017, 2022 & 2028)
    3.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028)
    3.4 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017, 2022 & 2028)
    3.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028)
4 Global Alpha- Antitrypsin Deficiency Treatment Competitor Landscape by Company
    4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Company
        4.1.1 Top Global Alpha- Antitrypsin Deficiency Treatment Companies Ranked by Revenue (2021)
        4.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue by Player (2017-2022)
    4.2 Global Alpha- Antitrypsin Deficiency Treatment Concentration Ratio (CR)
        4.2.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Alpha- Antitrypsin Deficiency Treatment in 2021
        4.2.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Alpha- Antitrypsin Deficiency Treatment Headquarters, Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Alpha- Antitrypsin Deficiency Treatment Headquarters and Area Served
        4.3.2 Global Alpha- Antitrypsin Deficiency Treatment Companies Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Alpha- Antitrypsin Deficiency Treatment Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Alpha- Antitrypsin Deficiency Treatment Market Size by Company
        4.5.1 Top Alpha- Antitrypsin Deficiency Treatment Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region
    5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2017-2028)
        5.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017-2022
        5.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
        6.1.2 North America Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
        6.3.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
        6.4.2 Latin America Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 Adverum Biotechnologies, Inc.
        7.1.1 Adverum Biotechnologies, Inc. Company Details
        7.1.2 Adverum Biotechnologies, Inc. Business Overview
        7.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.1.5 Adverum Biotechnologies, Inc. Recent Development
    7.2 Alnylam Pharmaceuticals, Inc.
        7.2.1 Alnylam Pharmaceuticals, Inc. Company Details
        7.2.2 Alnylam Pharmaceuticals, Inc. Business Overview
        7.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
    7.3 Applied Genetic Technologies Corporation
        7.3.1 Applied Genetic Technologies Corporation Company Details
        7.3.2 Applied Genetic Technologies Corporation Business Overview
        7.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
        7.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.3.5 Applied Genetic Technologies Corporation Recent Development
    7.4 Arrowhead Pharmaceuticals, Inc.
        7.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
        7.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview
        7.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
    7.5 Carolus Therapeutics, Inc.
        7.5.1 Carolus Therapeutics, Inc. Company Details
        7.5.2 Carolus Therapeutics, Inc. Business Overview
        7.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.5.5 Carolus Therapeutics, Inc. Recent Development
    7.6 Cevec Pharmaceuticals GmbH
        7.6.1 Cevec Pharmaceuticals GmbH Company Details
        7.6.2 Cevec Pharmaceuticals GmbH Business Overview
        7.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
        7.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.6.5 Cevec Pharmaceuticals GmbH Recent Development
    7.7 Dicerna Pharmaceuticals, Inc.
        7.7.1 Dicerna Pharmaceuticals, Inc. Company Details
        7.7.2 Dicerna Pharmaceuticals, Inc. Business Overview
        7.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
    7.8 Digna Biotech, S.L.
        7.8.1 Digna Biotech, S.L. Company Details
        7.8.2 Digna Biotech, S.L. Business Overview
        7.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.8.5 Digna Biotech, S.L. Recent Development
    7.9 Editas Medicine, Inc.
        7.9.1 Editas Medicine, Inc. Company Details
        7.9.2 Editas Medicine, Inc. Business Overview
        7.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.9.5 Editas Medicine, Inc. Recent Development
    7.10 Grifols, S.A.
        7.10.1 Grifols, S.A. Company Details
        7.10.2 Grifols, S.A. Business Overview
        7.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.10.5 Grifols, S.A. Recent Development
    7.11 Inhibrx
        7.11.1 Inhibrx Company Details
        7.11.2 Inhibrx Business Overview
        7.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
        7.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.11.5 Inhibrx Recent Development
    7.12 Intellia Therapeutics, Inc.
        7.12.1 Intellia Therapeutics, Inc. Company Details
        7.12.2 Intellia Therapeutics, Inc. Business Overview
        7.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.12.5 Intellia Therapeutics, Inc. Recent Development
    7.13 International Stem Cell Corporation
        7.13.1 International Stem Cell Corporation Company Details
        7.13.2 International Stem Cell Corporation Business Overview
        7.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
        7.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.13.5 International Stem Cell Corporation Recent Development
    7.14 Ionis Pharmaceuticals, Inc.
        7.14.1 Ionis Pharmaceuticals, Inc. Company Details
        7.14.2 Ionis Pharmaceuticals, Inc. Business Overview
        7.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.14.5 Ionis Pharmaceuticals, Inc. Recent Development
    7.15 Kamada Ltd.
        7.15.1 Kamada Ltd. Company Details
        7.15.2 Kamada Ltd. Business Overview
        7.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.15.5 Kamada Ltd. Recent Development
    7.16 Polyphor Ltd.
        7.16.1 Polyphor Ltd. Company Details
        7.16.2 Polyphor Ltd. Business Overview
        7.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.16.5 Polyphor Ltd. Recent Development
    7.17 ProMetic Life Sciences Inc.
        7.17.1 ProMetic Life Sciences Inc. Company Details
        7.17.2 ProMetic Life Sciences Inc. Business Overview
        7.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.17.5 ProMetic Life Sciences Inc. Recent Development
    7.18 rEVO Biologics, Inc.
        7.18.1 rEVO Biologics, Inc. Company Details
        7.18.2 rEVO Biologics, Inc. Business Overview
        7.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.18.5 rEVO Biologics, Inc. Recent Development
    7.19 Sangamo BioSciences, Inc.
        7.19.1 Sangamo BioSciences, Inc. Company Details
        7.19.2 Sangamo BioSciences, Inc. Business Overview
        7.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
        7.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
        7.19.5 Sangamo BioSciences, Inc. Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer
List of Tables
    Table 1. Alpha- Antitrypsin Deficiency Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Alpha- Antitrypsin Deficiency Treatment Market Trends
    Table 3. Alpha- Antitrypsin Deficiency Treatment Market Drivers
    Table 4. Alpha- Antitrypsin Deficiency Treatment Market Challenges
    Table 5. Alpha- Antitrypsin Deficiency Treatment Market Restraints
    Table 6. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Alpha- Antitrypsin Deficiency Treatment Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Player, 2017-2022
    Table 13. Global Alpha- Antitrypsin Deficiency Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Alpha- Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2021)
    Table 15. Top Players of Alpha- Antitrypsin Deficiency Treatment in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Alpha- Antitrypsin Deficiency Treatment Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Alpha- Antitrypsin Deficiency Treatment Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Alpha- Antitrypsin Deficiency Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Alpha- Antitrypsin Deficiency Treatment Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Alpha- Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Alpha- Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Alpha- Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Adverum Biotechnologies, Inc. Company Details
    Table 31. Adverum Biotechnologies, Inc. Business Overview
    Table 32. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 33. Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 34. Adverum Biotechnologies, Inc. Recent Development
    Table 35. Alnylam Pharmaceuticals, Inc. Company Details
    Table 36. Alnylam Pharmaceuticals, Inc. Business Overview
    Table 37. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 38. Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 39. Alnylam Pharmaceuticals, Inc. Recent Development
    Table 40. Applied Genetic Technologies Corporation Company Details
    Table 41. Applied Genetic Technologies Corporation Business Overview
    Table 42. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product
    Table 43. Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 44. Applied Genetic Technologies Corporation Recent Development
    Table 45. Arrowhead Pharmaceuticals, Inc. Company Details
    Table 46. Arrowhead Pharmaceuticals, Inc. Business Overview
    Table 47. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 48. Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 49. Arrowhead Pharmaceuticals, Inc. Recent Development
    Table 50. Carolus Therapeutics, Inc. Company Details
    Table 51. Carolus Therapeutics, Inc. Business Overview
    Table 52. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 53. Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 54. Carolus Therapeutics, Inc. Recent Development
    Table 55. Cevec Pharmaceuticals GmbH Company Details
    Table 56. Cevec Pharmaceuticals GmbH Business Overview
    Table 57. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product
    Table 58. Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 59. Cevec Pharmaceuticals GmbH Recent Development
    Table 60. Dicerna Pharmaceuticals, Inc. Company Details
    Table 61. Dicerna Pharmaceuticals, Inc. Business Overview
    Table 62. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 63. Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 64. Dicerna Pharmaceuticals, Inc. Recent Development
    Table 65. Digna Biotech, S.L. Company Details
    Table 66. Digna Biotech, S.L. Business Overview
    Table 67. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product
    Table 68. Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 69. Digna Biotech, S.L. Recent Development
    Table 70. Editas Medicine, Inc. Company Details
    Table 71. Editas Medicine, Inc. Business Overview
    Table 72. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 73. Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 74. Editas Medicine, Inc. Recent Development
    Table 75. Grifols, S.A. Company Details
    Table 76. Grifols, S.A. Business Overview
    Table 77. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product
    Table 78. Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 79. Grifols, S.A. Recent Development
    Table 80. Inhibrx Company Details
    Table 81. Inhibrx Business Overview
    Table 82. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product
    Table 83. Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 84. Inhibrx Recent Development
    Table 85. Intellia Therapeutics, Inc. Company Details
    Table 86. Intellia Therapeutics, Inc. Business Overview
    Table 87. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 88. Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 89. Intellia Therapeutics, Inc. Recent Development
    Table 90. International Stem Cell Corporation Company Details
    Table 91. International Stem Cell Corporation Business Overview
    Table 92. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product
    Table 93. International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 94. International Stem Cell Corporation Recent Development
    Table 95. Ionis Pharmaceuticals, Inc. Company Details
    Table 96. Ionis Pharmaceuticals, Inc. Business Overview
    Table 97. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 98. Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 99. Ionis Pharmaceuticals, Inc. Recent Development
    Table 100. Kamada Ltd. Company Details
    Table 101. Kamada Ltd. Business Overview
    Table 102. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product
    Table 103. Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 104. Kamada Ltd. Recent Development
    Table 105. Polyphor Ltd. Company Details
    Table 106. Polyphor Ltd. Business Overview
    Table 107. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product
    Table 108. Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 109. Polyphor Ltd. Recent Development
    Table 110. ProMetic Life Sciences Inc. Company Details
    Table 111. ProMetic Life Sciences Inc. Business Overview
    Table 112. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 113. ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 114. ProMetic Life Sciences Inc. Recent Development
    Table 115. rEVO Biologics, Inc. Company Details
    Table 116. rEVO Biologics, Inc. Business Overview
    Table 117. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 118. rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 119. rEVO Biologics, Inc. Recent Development
    Table 120. Sangamo BioSciences, Inc. Company Details
    Table 121. Sangamo BioSciences, Inc. Business Overview
    Table 122. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product
    Table 123. Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022) & (US$ Million)
    Table 124. Sangamo BioSciences, Inc. Recent Development
    Table 125. Research Programs/Design for This Report
    Table 126. Key Data Information from Secondary Sources
    Table 127. Key Data Information from Primary Sources
List of Figures
    Figure 1. Alpha- Antitrypsin Deficiency Treatment Product Picture
    Figure 2. Global Alpha- Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Alpha- Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million)
    Figure 4. United States Alpha- Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Alpha- Antitrypsin Deficiency Treatment Market Size 2017-2028 (US$ Million)
    Figure 6. United States Alpha- Antitrypsin Deficiency Treatment Market Share in Global 2017-2028
    Figure 7. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
    Figure 8. Product Picture of CT-2009
    Figure 9. Product Picture of POL-6014
    Figure 10. Product Picture of ARO-AAT
    Figure 11. Product Picture of ALNAAT-02
    Figure 12. Product Picture of Others
    Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type in 2022 & 2028
    Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
    Figure 16. United States Alpha- Antitrypsin Deficiency Treatment Market Share by Type in 2022 & 2028
    Figure 17. United States Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2017-2028)
    Figure 19. Product Picture of Clinic
    Figure 20. Product Picture of Hospital
    Figure 21. Product Picture of Others
    Figure 22. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application in 2022 & 2028
    Figure 23. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
    Figure 25. United States Alpha- Antitrypsin Deficiency Treatment Market Share by Application in 2022 & 2028
    Figure 26. United States Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2017-2028)
    Figure 28. North America Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. U.A.E Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Adverum Biotechnologies, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 57. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 58. Applied Genetic Technologies Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 59. Arrowhead Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 60. Carolus Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 61. Cevec Pharmaceuticals GmbH Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 62. Dicerna Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 63. Digna Biotech, S.L. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 64. Editas Medicine, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 65. Grifols, S.A. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 66. Inhibrx Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 67. Intellia Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 68. International Stem Cell Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 69. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 70. Kamada Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 71. Polyphor Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 72. ProMetic Life Sciences Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 73. rEVO Biologics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 74. Sangamo BioSciences, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2017-2022)
    Figure 75. Bottom-up and Top-down Approaches for This Report
    Figure 76. Data Triangulation
    Figure 77. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Frequently Asked Questions
Alpha- Antitrypsin Deficiency Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Alpha- Antitrypsin Deficiency Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Alpha- Antitrypsin Deficiency Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports